Details

Autor(en) / Beteiligte

• Miyachi, Hideaki
• Konishi, Takaaki
• Kumazawa, Ryosuke
• Matsui, Hiroki
• Shimizu, Sayuri
• Fushimi, Kiyohide
• Matsue, Hiroyuki
• Yasunaga, Hideo

Titel

Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan

Ist Teil von

• Journal of the American Academy of Dermatology, 2022-06, Vol.86 (6), p.1266-1274

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Because generalized pustular psoriasis (GPP) is rare, there are few studies reporting treatments and outcomes for large numbers of patients. To report treatments and outcomes in a large cohort of patients hospitalized with GPP. Using a Japanese national inpatient database, we identified 1516 patients with GPP who required hospitalization between July 2010 and March 2019. We categorized patients into 3 medication groups: biologics (294 patients), oral agents without biologics (948 patients), and systemic corticosteroids only (274 patients). We investigated their characteristics, treatments, and outcomes. Mean age was 66 years (interquartile range: 52-77 years). Fifty patients (3.3%) were admitted to the intensive care unit, 125 (8.2%) required blood pressure support, and 63 (4.2%) died. Patients who received biologics were younger and had fewer comorbidities. In-hospital mortality was lower in the biologics group (1.0% [biologics group] vs 3.7% [oral-agents group] vs 9.1% [corticosteroids-only group]; P < .001) as was morbidity (5.4% vs 8.2% vs 12%, respectively; P = .02). Among those who received biologics, IL-17 inhibitor use increased over time, with in-hospital mortality and morbidity comparable to those of tumor necrosis factor inhibitors. Retrospective study design. Some patients received multiple medications. Biologic treatments showed favorable outcomes compared with other treatments.